MA30604B1 - Agonistes de ep2 - Google Patents

Agonistes de ep2

Info

Publication number
MA30604B1
MA30604B1 MA31593A MA31593A MA30604B1 MA 30604 B1 MA30604 B1 MA 30604B1 MA 31593 A MA31593 A MA 31593A MA 31593 A MA31593 A MA 31593A MA 30604 B1 MA30604 B1 MA 30604B1
Authority
MA
Morocco
Prior art keywords
agonists
methods
compositions
glaucoma
treating
Prior art date
Application number
MA31593A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30604B1 publication Critical patent/MA30604B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES AGONISTES DE EP2, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES COMPOSÉS, ET DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS ET COMPOSITIONS POUR ABAISSER LA PRESSION INTRA-OCULAIRE ET AINSI TRAITER UN GLAUCOME.
MA31593A 2006-07-28 2009-01-28 Agonistes de ep2 MA30604B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
MA30604B1 true MA30604B1 (fr) 2009-07-01

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31593A MA30604B1 (fr) 2006-07-28 2009-01-28 Agonistes de ep2

Country Status (26)

Country Link
US (2) US7622475B2 (fr)
EP (1) EP2059507B1 (fr)
JP (1) JP4583500B2 (fr)
KR (1) KR101088942B1 (fr)
AP (1) AP2009004754A0 (fr)
AR (1) AR062122A1 (fr)
AU (1) AU2007280130B2 (fr)
BR (1) BRPI0714683A2 (fr)
CA (1) CA2659184C (fr)
CL (1) CL2007002207A1 (fr)
CR (1) CR10554A (fr)
EA (1) EA200970067A1 (fr)
EC (1) ECSP099071A (fr)
GT (1) GT200700064A (fr)
HK (1) HK1133876A1 (fr)
IL (1) IL196355A0 (fr)
MA (1) MA30604B1 (fr)
MX (1) MX2009001062A (fr)
NO (1) NO20090738L (fr)
NZ (1) NZ573964A (fr)
PE (1) PE20080408A1 (fr)
RS (1) RS20090002A (fr)
TN (1) TN2009000028A1 (fr)
TW (1) TWI372757B (fr)
UY (1) UY30511A1 (fr)
WO (1) WO2008015517A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904655T4 (tr) * 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
EP2415763B1 (fr) 2009-03-30 2016-01-27 Ube Industries, Ltd. Composition pharmaceutique pour la prévention ou le traitement du glaucome
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
CA2773997A1 (fr) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Composes aniline
CA2773998A1 (fr) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Composes carbonyle substitues
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
KR20120101722A (ko) * 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
KR20140003395A (ko) * 2010-08-17 2014-01-09 알러간, 인코포레이티드 각막 혼탁 치료용 ep2 또는 ep4 항진제들
SG11201400555SA (en) 2011-09-16 2014-04-28 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
WO2013109991A1 (fr) * 2012-01-20 2013-07-25 Acucela Inc. Composés hétérocycliques substitués pour le traitement d'une maladie
CN104507906B (zh) 2012-05-03 2017-04-12 塔科达有限责任公司 新的ep2受体激动剂
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US9676720B2 (en) * 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) * 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020115695A1 (en) * 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
JP2005513030A (ja) 2001-11-30 2005-05-12 ファイザー・プロダクツ・インク 医薬組成物及びｅｐ２受容体選択的アゴニストの投与方法
KR20040077884A (ko) * 2002-01-31 2004-09-07 화이자 프로덕츠 인코포레이티드 （3-｛〔（4-3급-뷰틸-벤질）-（피리딘-3-설폰일）-아미노〕-메틸｝-페녹시）-아세트산의 대사산물
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ｅｐ2 선택적 수용체 효능제의 용도
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
EP2059507A2 (fr) 2009-05-20
KR20090023507A (ko) 2009-03-04
US20100105905A1 (en) 2010-04-29
EA200970067A1 (ru) 2009-08-28
UY30511A1 (es) 2008-02-29
MX2009001062A (es) 2009-02-06
GT200700064A (es) 2009-06-18
ECSP099071A (es) 2009-02-27
CL2007002207A1 (es) 2008-02-01
CA2659184A1 (fr) 2008-02-07
AU2007280130A1 (en) 2008-02-07
NZ573964A (en) 2010-11-26
US7622475B2 (en) 2009-11-24
WO2008015517A3 (fr) 2008-06-12
IL196355A0 (en) 2009-09-22
WO2008015517A2 (fr) 2008-02-07
KR101088942B1 (ko) 2011-12-01
EP2059507B1 (fr) 2013-03-20
TWI372757B (en) 2012-09-21
TW200817360A (en) 2008-04-16
AU2007280130B2 (en) 2011-09-22
CA2659184C (fr) 2012-02-21
BRPI0714683A2 (pt) 2013-03-26
JP2009544751A (ja) 2009-12-17
NO20090738L (no) 2009-04-27
CR10554A (es) 2009-02-10
AR062122A1 (es) 2008-10-15
AP2009004754A0 (en) 2009-02-28
HK1133876A1 (en) 2010-04-09
PE20080408A1 (es) 2008-04-28
TN2009000028A1 (fr) 2010-08-19
US20080045545A1 (en) 2008-02-21
JP4583500B2 (ja) 2010-11-17
RS20090002A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
MA30604B1 (fr) Agonistes de ep2
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA30765B1 (fr) Derives innovants du thiophene
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
WO2008056259A3 (fr) Dérivés d'oxazole utilisés en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same